Obtaining Orphan Product Designation Challenges and pitfalls
description
Transcript of Obtaining Orphan Product Designation Challenges and pitfalls
Obtaining Orphan Product Designation
Challenges and pitfalls
Marlene E. Haffner, MD, MPHPresident and CEOHaffner Associates, [email protected]
Requirements for Designation
• Population less than 200,000 in the US • Reasonable consideration that the product
will have utility for the stated indication• Need some data – preferably clinical or
animal• IND helpful but not a requirement
2
Obtaining your designation
• Orphan Products “tip sheet”• http://www.fda.gov/ForIndustry/DevelopingPr
oductsforRareDiseasesConditions/HowtoapplyforOrphanProductDesignation/ucm135122.htm
• Aka – www.fda.gov/orphan - how to apply for orphan products designation
3
What is the Disease – what is a subset
• Define the disease• Is that what you are treating or are you
treating a symptom of the disease?• What is a subset of a disease?
A part of a disease that can be treated by the drug. However, the disease as a whole cannot be treated by the drug. WHY??
4
When is a subset valid • NOT because that is what you wish to study• Because the drug is not useful for the “larger” disease
– It is too toxic– Genetic markers make it ineffective – HER2 +,
KRAS mutant – except in the subset• More effective treatments for other segments of the
disease – surgery for stage 1• Pediatric manifestations of a disease are valid
5
Not always straightforward
• Erythropoietin for anemia of:– ESRD– Anemia of prematurity– Blackfan Diamond syndrome
• Product for obesity in– Obese adults– Prader Willi syndrome
6
How is subsetting determined
• Review the disease• What is the mechanism of action in the
disease• Are you treating the disease or a symptom of
the disease – if a symptom, then is the symptom prevalence attributed only to “that” disease – post-op pain vs pain
7
Defining Prevalence
• If an oncology drug – NIH SEER Data – http://Seer.cancer.gov
• If a metabolic disease – published literature; Mendelian inheritance (McKusick) – www.OMIM.org
• If infectious disease – start with CDC• Sometimes hospital discharge summaries• All other – published literature – texts and current
articles in peer reviewed literature• Not always easy
8
Establishing Prevalence
• Use of experts – only in VERY rare diseases• Discuss issues of defining prevalence in
your designation request• Be straightforward. The OOPD (Office of
Orphan Products Development) reads the literature
• If a range – OOPD will assume upper end• Importance in higher numbers - >100,000
9
Non Profitability in 7 years
• Has occurred only 3 times since 1983• Twice for products to treat narcotic addiction• Once for a product already marketed for
another indication and about to go off patent• Difficult hurdle; must open books for review• Developing an unprofitable product is “not
the usual.”
10
THANK YOU
?11
12